What does this research mean for the field?

The AS01E-adjuvanted RSVPreF3 vaccine is immunologically noninferior in adults aged 18-49 with underlying conditions compared to adults aged ≥60 years. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

This study aims to evaluate the immunogenicity and safety of the RSV vaccine in younger adults at risk compared to older adults.

March 1, 2026

Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years.

Key Points

This study aims to evaluate the immunogenicity and safety of the RSV vaccine in younger adults at risk compared to older adults.
Comparison of immune responses in adults aged 18-49 with underlying conditions and adults aged ≥60 years.
Assessment of safety profiles post-vaccination.
Monitoring immune responses up to 6 months post-vaccination.
The vaccine showed noninferior immunogenicity in younger adults compared to older adults.
Robust immune responses were observed in the younger cohort.
The safety profile of the vaccine was deemed acceptable.

Abstract

Adjuvanted RSVPreF3 was immunologically noninferior in 18-49-year-olds with underlying conditions compared with ≥60-year-olds in whom efficacy was previously demonstrated, supporting efficacy inference in this younger population. Up to 6 months postvaccination, the vaccine elicited robust immune responses, and the safety profile was acceptable. Clinical Trial Registration: NCT06389487.

Bookmark

Cite This Study

Snyman et al. (Fri,) studied this question.

synapsesocial.com/papers/69a3d89aec16d51705d2f97d https://doi.org/https://doi.org/10.1093/cid/ciag058

Bookmark